Colombia INVIMA registration INVIMA 2022RD-0007679

CLINITEST RAPID COVID-19 ANTIGEN SELF-TEST

Name: CLINITEST RAPID COVID-19 ANTIGEN SELF-TEST — Colombia INVIMA registration INVIMA 2022RD-0007679
Creator: SIEMENS HEALTHCARE S.A.S
Keywords: CLINITEST RAPID COVID-19 ANTIGEN SELF-TEST, INVIMA 2022RD-0007679, III, INVIMA registration

HEALGEN SCIENTIFIC LIMITED LIABILITY COMPANYIIIColombia INVIMAExpires September 20, 2027

VerifiedINVIMA · official registry

Device classification

Registered product (Spanish): CLINITEST RAPID COVID-19 ANTIGEN SELF-TEST
Risk class / Clase de riesgo: III
Product group (Spanish): REACTIVO DIAGNOSTICO

Registration information

Sanitary registration: INVIMA 2022RD-0007679
Expediente: 20230235
Status / Estado: Active
Expiry date: September 20, 2027

Registration holder / Titular

Name: SIEMENS HEALTHCARE S.A.S

Associated party / Rol

Name: HEALGEN SCIENTIFIC LIMITED LIABILITY COMPANY
Role: FABRICANTE
Country: ESTADOS UNIDOS DE AMÉRICA
Manufacturer: HEALGEN SCIENTIFIC LIMITED LIABILITY COMPANY

About this record

Access comprehensive regulatory information for CLINITEST RAPID COVID-19 ANTIGEN SELF-TEST in the Colombia medical device market through Pure Global AI's free database. This III medical device is registered under INVIMA sanitary registration INVIMA 2022RD-0007679, held by SIEMENS HEALTHCARE S.A.S and associated with HEALGEN SCIENTIFIC LIMITED LIABILITY COMPANY (FABRICANTE). The registration expires on September 20, 2027.

This page provides complete registration details including product group (REACTIVO DIAGNOSTICO), holder and associated-party information, and regulatory data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.